OCTOPIT (Optical Coherence Tomography [OCT] in Optimising timing of intervention for PItuitary Tumours): A pilot survey for practitioners evaluating the role of OCT in managing asymptomatic non-functioning pituitary adenomas
The OCTOPIT (Optical Coherence Tomography in Optimising Timing of Intervention for Pituitary Tumours) pilot survey aims to assess the current global utilisation of Optical Coherence Tomography (OCT) in managing asymptomatic non-functioning pituitary adenomas. By gathering your expert opinions, we hope to gain valuable insights into the potential role of OCT in optimising patient care.This survey is a precursor to the OCTOPIT study, an upcoming observational, multicentre study organised by the Institute of Neurosciences in Glasgow, in partnership with the University of Glasgow. The primary objective of the OCTOPIT study is to investigate the clinical utility of OCT in guiding treatment decisions and improving outcomes for individuals with non-functioning asymptomatic pituitary adenomas.Your participation in this survey is essential to shaping the future of OCT in pituitary tumour management. We invite you to contribute your expertise and insights to this collaborative research.
Back
Next
What is your primary speciality?
*
Neurosurgery
Ophthalmology
Neuro-ophthalmology
Endocrinology
Other
What is your grade?
*
Consultant/Attending
Fellow
Registrar/Resident
Other
How many years of experience do you have in your current role?
*
0-5 years
6-10 years
>10 years
How would you describe your main place of work?
*
Academic/University hospital
District General/Community Hospital
Private Hospital
Other
In which region is your practice based?
*
UK/Republic of Ireland
Western Europe (excluding UK and ROI) – e.g., France, Germany, Italy, Spain
Eastern Europe – e.g., Poland, Russia, Czech Republic
North America – USA, Canada
Central and South America – e.g., Brazil, Argentina, Mexico
Middle East – e.g., UAE, Saudi Arabia, Jordan
South Asia – e.g., India, Pakistan, Bangladesh
East Asia – e.g., China, Japan, South Korea
Southeast Asia – e.g., Singapore, Malaysia, Thailand
Australasia – Australia, New Zealand, Pacific Islands
North Africa (e.g., Egypt, Morocco)
Sub-Saharan Africa - e.g. Sudan, Nigeria
Other
If you answered UK/ROI to the question above, please select which specific region is your practice based in?
East of England
East Midlands
Kent, Surrey, and Sussex (KSS)
London
Mersey
North East
North West
Northern Ireland
Scotland
South West
Thames Valley
Wales
Wessex
West Midlands
Yorkshire and the Humber
Are you familiar with Optical Coherence Tomography technology and its use in visual assessment?
*
Yes
No
Do you have access to OCT within your department or via referral to an ophthalmology service for the evaluation of pituitary adenomas?
*
Yes
No
Please tell us which OCT scanner do you use or have access to?
*
Topcon Triton
Heidelberg spectralis
Other
Do you routinely use OCT in the evaluation of your asymptomatic non-functioning pituitary adenoma patients?
*
Yes
No
Do OCT findings influence your decision-making process for managing asymptomatic non-functioning pituitary adenomas?
*
Yes
No
In your practice, how often are OCT findings discussed in multidisciplinary team (MDT) meetings prior to surgical intervention for asymptomatic non-functioning pituitary adenomas?
*
Never
1
2
3
4
Always
5
1 is Never, 5 is Always
Do you believe that OCT should be part of the routine preoperative evaluation for all patients with non-functioning pituitary adenomas?
*
Yes
No
I don't know
In your opinion, does OCT provide useful prognostic information regarding visual outcomes after surgical decompression? [5-point-Likert 1=strongly disagree, 2=disagree, 3=unsure, 4=agree, 5=strongly agree]
*
Strongly Disagree
1
2
3
4
Strongly Agree
5
1 is Strongly Disagree, 5 is Strongly Agree
Do you use OCT findings to inform patient discussions regarding surgical versus conservative management of asymptomatic non-functioning pituitary adenomas?
*
Yes
No
Would you be interested in participating in a prospective study on the use of OCT in the management of asymptomatic non-functioning pituitary adenomas?
*
Yes
No
I don't manage patients with pituitary tumours
Please provide your email address if you'd like to receive updates or collaborate on the next phase of this project
example@example.com
Submit
Should be Empty: